Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
NCT06128304 · View on ClinicalTrials.gov ↗
Study Summary
While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparative effectiveness of a Core set of implementation strategies versus a Core+ (enhanced) set of implementation strategies to implement cervical cancer screening, onsite treatment, referral and referral completion, treatment, and retention in care among WLHIV. The overarching goal is to improve the health and life expectancy of WLHIV with co-occurring cervical cancer.
Conditions Studied
Interventions
- OTHER Core Implementation strategies
- OTHER Core+ Enhanced Implementation Strategies
Study Locations (2)
California
- UC San Diego — La Jolla
Enugu State
- University of Nigeria, Nsukka — Enugu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,436 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128304
The ClinicalTrials.gov registry entry for NCT06128304 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,436 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 823 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions — of which Core Implementation strategies is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06128304 reports 2 study locations spanning 2 distinct geographic areas — top geographies include California, Enugu State. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06128304 about?
NCT06128304 is a clinical study titled "ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services". While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available ...
What is the current status of trial NCT06128304?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,436 participants. The study started on 2023-11-13. Estimated completion is 2027-08-31.
What conditions does trial NCT06128304 study?
This clinical trial studies the following conditions: HIV, Cervical Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06128304?
The interventions under investigation include: Core Implementation strategies (OTHER), Core+ Enhanced Implementation Strategies (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06128304?
This trial is sponsored by University of California, San Diego, which has 823 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06128304 being conducted?
This trial has 2 study locations across California, Enugu State. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.